Peptilogics Enrolls First U.K. Patient in 240-Person Pivotal Trial of Zaloganan, an Engineered Antibacterial Peptide for Infected Knee Replacements
Leeds Teaching Hospitals enrolled the first patient outside the U.S. in RETAIN (NCT07214311), a randomized, double-blind, placebo-controlled Phase 2/3 trial of zaloganan (PLG0206) in people having their infected knee implant cleaned and kept in place rather than replaced. The trial plans about 240 patients at 50 sites in the U.S., U.K., and Australia, with treatment failure within 12 months as its primary endpoint. Peptilogics says one of 13 patients had a recurrence in its open-label Phase 1b study, compared with published 12-month failure rates of 35% to 55% under standard care, a comparison across different studies.